The Procter & Gamble Company

▲ Bull Case

• ◆Volume recovery is real and durable. Q3 FY2026's +2% volume (first positive in ~8 quarters) reflects consumers returning to premium brands as the inflationary shock fades. By FY2027, organic +4–5%/yr + tariff normalization = re-rating catalyst from 19.8x toward 23–24x P/E.
• ◆China/SK-II recovery is 1–2 quarters away. Greater China was –2% organic in FY2025 on premium consumer weakness. Historical pattern: Chinese premium consumer cycles recover within 2–3 years. When SK-II China turns positive (expected late FY2026 or early FY2027), it removes the last bear anchor and adds ~$0.30–0.50/share annual uplift.
• ◆New CEO portfolio discipline unlocks value. Jejurikar has 36 years at P&G in highest-margin businesses (Asia, Beauty, Baby). His investor day announcement — whether productivity program, portfolio simplification, or enhanced China strategy — has historically driven 8–12% stock reactions. Family Care divestiture would be immediately accretive.

▼ Bear Case

• ◆Q3 FY2026 volume was tariff-driven restock, not demand. If retailers pre-bought ahead of tariff implementation, Q4 FY2026 will show reversal — confirming underlying end-consumer demand is only +0–1%. This breaks the recovery thesis and triggers de-rating to 16–17x.
• ◆Private label secular acceleration is underpriced. Circana data shows private label household products at 22% dollar share in 2025 vs. 20% pre-COVID. The structural force (higher-quality private label + inflation-sensitized consumers) continues post-tariff. Path to 25% share eliminates volume growth without commensurate pricing power.
• ◆CEO transition creates strategic uncertainty. Jejurikar has not yet made a major strategic move. Any misreading of competition (over-investing in failing brands, under-cutting on pricing, or large M&A destroying capital) could impair the capital allocation track record justifying 20x+ P/E.

“The central debate is 'Is P&G's +2% organic growth a recovery trajectory or a dead-cat bounce?' Bulls argue the inflationary pricing cycle (FY2022–2024) produced expected volume hangover that is now over; volume is recovering as consumers absorb higher prices; Tide/Pampers loyalty proves durable (private label at 22% stable, not accelerating); at 20x forward P/E + 5% FCF yield the stock is fairly cheap. Bears counter that pricing structurally taught consumers private-label is 'good enough'; Aldi/Lidl/Target improved since 2022; Q3 volume reflects retailer tariff restocking not genuine demand; FY2027 organic will be +1–2% at best. Resolution: Q4 FY2026 scan data (Nielsen/Circana) and earnings report (August 2026) will be definitive.”

• ◆Q4 FY2026 Earnings + FY2027 Guide (August 2026): Organic ≥3% and guide ≥+4% confirm recovery; <2% organic = elevate bear to 30%
• ◆Jejurikar Investor Day (Sep–Oct 2026): New CEO's first major strategic declaration; portfolio restructuring announcement significant
• ◆US-China Tariff Resolution (Ongoing 2026): Each $100M reduction in $500M headwind = ~$0.06/share EPS impact, ~$1.20 stock impact
• ◆China/SK-II Q1 FY2027 Organic (Nov 2026): Greater China ≥0% removes bear anchor and adds ~$0.30–0.50/share uplift
• ◆Private Label Share Data — Circana H2 2025 (Jan 2027): Stabilization at 22% bullish; acceleration to 23%+ signals structural headwind

• ◆Organic stagnation (+0–1% vol × 3 qtrs): 25% probability, high severity — primary bear driver; kill switch → REDUCE 25%
• ◆Tariff persistence >$400M FY2027+: 20% probability, medium severity — manageable via pricing/sourcing but mars EPS growth
• ◆Rate spike (10yr UST >5.5%): 20% probability, medium severity — bond-proxy de-rating but sector-wide, not P&G-specific
• ◆Private label >24% dollar share: 15% probability, high severity — structural loss; kill switch if >23% for 2 consecutive Circana reports
• ◆CEO disruption/bad M&A: 10% probability, medium severity — new CEO track record strong but first move unproven